U.S. markets close in 3 hours 22 minutes

Immunocore Holdings plc (IMCR)

NasdaqGS - NasdaqGS Precio en tiempo real. Moneda en USD.
Añadir a la lista de seguimiento
40.33+0.86 (+2.18%)
A partir del 12:37PM EDT. Mercado abierto.

Immunocore Holdings plc

92 Park Drive
Milton Park
Abingdon OX14 4RY
United Kingdom
44 12 3543 8600
https://www.immunocore.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo497

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Bahija Jallal Ph.D.CEO & Executive Director1.38M9.72M1961
Ms. Tina St. LegerChief Human Resources Officer509.12k790.91k1968
Mr. John Trainer M.B.A.SVP & Chief Operating OfficerN/DN/D1974
Mr. John Goll IIISVP, Finance & Chief Accounting OfficerN/DN/DN/D
Mr. Sean D. BuckleyVP & Chief Information OfficerN/DN/D1983
Clayton RobertsonHead of Investor RelationsN/DN/DN/D
Ms. Elizabeth Varki Jobes Esq., J.D.Chief Compliance OfficerN/DN/D1967
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Gestión corporativa

La calificación ISS Governance QuickScore de Immunocore Holdings plc a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.